Russell Surasky, DO
Neurology · Great Neck, NYNPI 1538484647
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $108,535 of the $139,359 with a category attached, or 77.9%. Alkermes, Inc. accounts for 82.4% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2019 at $107,203 and has fallen 98.7% since, to $1,341 in 2025. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 544 payments — averaging $256.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$115K
- MDD US Operations, LLC$19K
- AbbVie$1K
- Pfizer$527
- Johnson & Johnson$443
- Takeda Pharmaceuticals U.S.A., Inc.$411
- plus $3K from 35 others
What the payments were for
- Consulting fees$1,5001%
- Speaking & faculty fees$108,53578%
- Travel & lodging$20,04614%
- Food & beverage$9,2107%
- Education$690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$113,822
- Lucemyra/Lofexidine$17,361
- SPRAVATO$125
- NURTEC ODT$118
How this compares
$139,359 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 82 | $1,531 |
| Gabapentin | 183 | $1,297 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 39 | $1,194 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $992 |
| Ropinirole Hcl | 18 | $318 |
| Duloxetine Hcl | 28 | $298 |
| Baclofen | 16 | $228 |
| RizatriptanRizatriptan Benzoate | 14 | $226 |
| Tramadol Hcl | 40 | $160 |
| Prednisone | 27 | $79 |
| Meloxicam | 13 | $47 |
| Diazepam | 12 | $39 |
| Clonazepam | 11 | $20 |
Paid to pharmacies, not to this prescriber.
Other neurology in Great Neck
- Anthony GeraciGreat Neck$279K
- Noah RosenGreat Neck$272K
- Robert DuarteGreat Neck$250K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.